HPV vaccination for treating stubborn skin warts

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of the human papillomavirus (HPV) vaccine in treating refractory cutaneous warts by comparing it to a placebo. Participants aged 18 and older with a clinical diagnosis of cutaneous warts who have previously undergone treatment will be randomly assigned to receive either the HPV vaccine or a saline placebo. The study aims to assess the efficacy of the vaccine in resolving warts, which can be painful and disfiguring, and to provide a potentially less invasive treatment option. The trial will be conducted at multiple centers, ensuring a diverse participant pool.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Must be able to understand and provide written informed consent
2. Age 18 or older
3. Clinical diagnosis of cutaneous warts
4. Must have received prior treatment for cutaneous warts (such as curettage, cryotherapy, salicylic acid, intralesional Candida antigen injection, etc.)

Exclusion Criteria:

1. Untreated cutaneous warts
2. Anogenital warts
3. Oral warts
4. Treatment for cutaneous warts in the past 4 weeks
5. Active acute illness
6. Immunosuppression
7. Known hypersensitivity to HPV vaccination
8. Subjects may not receive any other investigational treatment
9. Pregnancy or planned pregnancy during the study period

Where it's running

• University of Utah Midvalley Health Center
  Salt Lake City, Utah, United States Recruiting
• VA Salt Lake City Health Care System
  Salt Lake City, Utah, United States Recruiting

Study contacts

• Principal investigator: Lowell Nicholson, MD — University of Utah Health Care System
• Study coordinator: Lowell Nicholson, MD
• Email: lowell.nicholson@hsc.utah.edu
• Phone: 801-581-2121

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cantharidin and occlusion in verruca epithelium: testing a topical treatment for common warts

  This Phase 3 study tests VP-102/TO-208 (cantharidin) vs. a vehicle to see if it clears common warts in people 2 years and older who have a normal immune system.

  Recruiting at 14 sites Phase 3 Verrica Pharmaceuticals Inc. · San Diego, California and 19 other locations · NCT07637734

• Heat combined with a hydrogen peroxide microneedle patch for common warts.

  This test will see if applying local heat at 44°C together with a microneedle patch that delivers 3% hydrogen peroxide clears common hand and foot warts in people aged 6 to 65.

  Recruiting First Hospital of China Medical University · Shenyang · NCT07534865

• Long-term follow-up of cantharidin (YCANTH/VP-102/TO-208) treatment for common warts

  This follow-up will try applying cantharidin (YCANTH/VP-102/TO-208) every ~21 days for up to four applications to see if it safely clears remaining common warts in people who completed earlier COVE studies.

  Recruiting at 12 sites Phase 3 Verrica Pharmaceuticals Inc. · Saint Augustine, Florida and 11 other locations · NCT07457918

• Using heat therapy to treat warts in special populations

  This study is testing if heat therapy can safely help treat warts in special groups like pregnant women, children, and people with autoimmune diseases or HIV.

  Recruiting First Hospital of China Medical University · Shenyang, Liaoning · NCT06827938

• Treatment of warts using heat and hydrogen peroxide

  This study is testing if using heat along with hydrogen peroxide can help people get rid of warts caused by a virus better than using either treatment alone.

  Recruiting at 2 sites First Hospital of China Medical University · Shenyang, Liaoning and 1 other locations · NCT06812065

• Using Candida antigen and a bivalent HPV vaccine to clear multiple common warts

  This study will test whether injections of Candida antigen, a bivalent HPV vaccine, or both can clear multiple common warts in people with persistent or widespread warts.

  Recruiting Phase 2 Zagazig University · Zagazig, Al Sharqia · NCT05291845

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.